{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:50:08Z","timestamp":1792698608680,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T00:00:00Z","timestamp":1771632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40271-6","type":"journal-article","created":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:09:35Z","timestamp":1771646975000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Plasma brain-derived tau: analytical and clinical validation of the first commercial immunoassay"],"prefix":"10.1038","volume":"16","author":[{"given":"Michel N.","family":"Nafash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Svirsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Kofler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O.","family":"Okonkwo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar L.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava M.","family":"Puccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,21]]},"reference":[{"key":"40271_CR1","doi-asserted-by":"publisher","first-page":"fcab086","DOI":"10.1093\/braincomms\/fcab086","volume":"3","author":"A Lle\u00f3","year":"2021","unstructured":"Lle\u00f3, A. Biomarkers in neurological disorders: a fast-growing market. Brain Commun. 3, fcab086 (2021).","journal-title":"Brain Commun."},{"key":"40271_CR2","doi-asserted-by":"crossref","unstructured":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 69, 89\u201395 (2001).","DOI":"10.1067\/mcp.2001.113989"},{"key":"40271_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrneurol.2014.232","volume":"11","author":"A Lle\u00f3","year":"2015","unstructured":"Lle\u00f3, A. et al. Cerebrospinal fluid biomarkers in trials for alzheimer and Parkinson diseases. Nat. Rev. Neurol. 11, 41\u201355 (2015).","journal-title":"Nat. Rev. Neurol."},{"key":"40271_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/978-981-32-9358-8_29","volume-title":"Tau Biology","author":"M Shoji","year":"2019","unstructured":"Shoji, M. Cerebrospinal fluid and plasma Tau as a biomarker for brain tauopathy. In Tau Biology (eds Takashima, A. et al.) 393\u2013405 (Springer, 2019). https:\/\/doi.org\/10.1007\/978-981-32-9358-8_29."},{"key":"40271_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.31887\/DCNS.2004.6.4\/hhampel","volume":"6","author":"H Hampel","year":"2004","unstructured":"Hampel, H. & Blennow, K. CSF Tau and \u03b2-amyloid as biomarkers for mild cognitive impairment. Dialogues Clin. Neurosci. 6, 379\u2013390 (2004).","journal-title":"Dialogues Clin. Neurosci."},{"key":"40271_CR6","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1093\/brain\/awac407","volume":"146","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Brain-derived tau: a novel blood-based biomarker for alzheimer\u2019s disease-type neurodegeneration. Brain 146, 1152\u20131165 (2023).","journal-title":"Brain"},{"key":"40271_CR7","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cca.2022.03.018","volume":"531","author":"J Telser","year":"2022","unstructured":"Telser, J., Risch, L., Saely, C. H., Grossmann, K. & Werner, P. P-tau217 in Alzheimer\u2019s disease. Clin. Chim. Acta 531, 100\u2013111 (2022).","journal-title":"Clin. Chim. Acta"},{"key":"40271_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/nrneurol.2010.4","volume":"6","author":"K Blennow","year":"2010","unstructured":"Blennow, K., Hampel, H., Weiner, M. & Zetterberg, H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131\u2013144 (2010).","journal-title":"Nat. Rev. Neurol."},{"key":"40271_CR9","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1038\/s44321-025-00229-z","volume":"17","author":"M Schuler","year":"2025","unstructured":"Schuler, M. et al. Alpha-synuclein misfolding as fluid biomarker for parkinson\u2019s disease measured with the iRS platform. EMBO Mol. Med. 17, 1203\u20131221 (2025).","journal-title":"EMBO Mol. Med."},{"key":"40271_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3390\/ijms26010389","volume":"26","author":"LX Yi","year":"2025","unstructured":"Yi, L. X., Tan, E. K. & Zhou, Z. D. The \u03b1-Synuclein seeding amplification assay for Parkinson\u2019s disease. Int. J. Mol. Sci. 26, 389 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"40271_CR11","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/alz.13518","volume":"20","author":"WS Brum","year":"2024","unstructured":"Brum, W. S. et al. Biological variation estimates of alzheimer\u2019s disease plasma biomarkers in healthy individuals. Alzheimer\u2019s Dement. 20, 1284\u20131297 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"40271_CR12","doi-asserted-by":"publisher","first-page":"103911","DOI":"10.1016\/j.drudis.2024.103911","volume":"29","author":"K Noda","year":"2024","unstructured":"Noda, K., Lim, Y., Goto, R., Sengoku, S. & Kodama, K. Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer\u2019s disease diagnosis. Drug Discov. Today 29, 103911 (2024).","journal-title":"Drug Discov. Today"},{"key":"40271_CR13","doi-asserted-by":"publisher","first-page":"8132","DOI":"10.3390\/ijms25158132","volume":"25","author":"D Krawczuk","year":"2024","unstructured":"Krawczuk, D., Kulczy\u0144ska-Przybik, A. & Mroczko, B. Clinical application of blood biomarkers in neurodegenerative diseases: present and future perspectives. Int. J. Mol. Sci. 25, 8132 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"40271_CR14","doi-asserted-by":"publisher","first-page":"683689","DOI":"10.3389\/fnagi.2022.683689","volume":"14","author":"A Hardy-Sosa","year":"2022","unstructured":"Hardy-Sosa, A. et al. Diagnostic accuracy of Blood-Based biomarker panels: A systematic review. Front. Aging Neurosci. 14, 683689 (2022).","journal-title":"Front. Aging Neurosci."},{"key":"40271_CR15","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12974-023-03003-5","volume":"21","author":"M Shi","year":"2024","unstructured":"Shi, M., Chu, F., Zhu, F. & Zhu, J. Peripheral blood amyloid-\u03b2 involved in the pathogenesis of Alzheimer\u2019s disease via impacting on peripheral innate immune cells. J. Neuroinflamm. 21, 5 (2024).","journal-title":"J. Neuroinflamm."},{"key":"40271_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40035-024-00461-6","volume":"14","author":"B Xu","year":"2025","unstructured":"Xu, B. et al. Peripheral proteinopathy in neurodegenerative diseases. Transl Neurodegener. 14, 2 (2025).","journal-title":"Transl Neurodegener"},{"key":"40271_CR17","doi-asserted-by":"publisher","first-page":"345","DOI":"10.3233\/JAD-150859","volume":"51","author":"BN Dugger","year":"2016","unstructured":"Dugger, B. N. et al. The presence of select Tau species in human peripheral tissues and their relation to Alzheimer\u2019s disease. J. Alzheimer\u2019s Disease 51, 345\u2013356 (2016).","journal-title":"J. Alzheimer\u2019s Disease"},{"key":"40271_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1152\/physrev.00006.2023","volume":"104","author":"R Balczon","year":"2024","unstructured":"Balczon, R. et al. Lung endothelium, tau, and amyloids in health and disease. Physiol. Rev. 104, 533\u2013587 (2024).","journal-title":"Physiol. Rev."},{"key":"40271_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg, H. et al. Plasma Tau levels in alzheimer\u2019s disease. Alzheimer\u2019s Res. Therapy. 5, 9 (2013).","journal-title":"Alzheimer\u2019s Res. Therapy"},{"key":"40271_CR20","doi-asserted-by":"publisher","first-page":"4764","DOI":"10.1002\/alz.13156","volume":"19","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Preanalytical stability of plasma\/serum brain-derived Tau. Alzheimer\u2019s Dement. 19, 4764\u20134770 (2023).","journal-title":"Alzheimer\u2019s Dement."},{"key":"40271_CR21","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/s41467-024-47286-5","volume":"15","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz, F. et al. Plasma brain-derived Tau is an amyloid-associated neurodegeneration biomarker in alzheimer\u2019s disease. Nat. Commun. 15, 2908 (2024).","journal-title":"Nat. Commun."},{"key":"40271_CR22","first-page":"e70143","volume":"11","author":"FK Clemmensen","year":"2025","unstructured":"Clemmensen, F. K. et al. The plasma p-tau217\/BD-tau ratio improves biomarker short-term variability in memory clinic patients. Alzheimer\u2019s Dementia: Transl. Res. Clin. Interv. 11, e70143 (2025).","journal-title":"Alzheimer\u2019s Dementia: Transl. Res. Clin. Interv."},{"key":"40271_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3389\/fncel.2019.00528","volume":"13","author":"SY Ng","year":"2019","unstructured":"Ng, S. Y. & Lee, A. Y. W. Traumatic brain injuries: pathophysiology and potential therapeutic targets. Front. Cell. Neurosci. 13, 528 (2019).","journal-title":"Front. Cell. Neurosci."},{"key":"40271_CR24","unstructured":"CDC. TBI Data. Traumatic Brain Injury & Concussion (2025). https:\/\/www.cdc.gov\/traumatic-brain-injury\/data-research\/index.html"},{"key":"40271_CR25","doi-asserted-by":"publisher","first-page":"102735","DOI":"10.1016\/j.bas.2023.102735","volume":"4","author":"I Hossain","year":"2024","unstructured":"Hossain, I., Marklund, N., Czeiter, E., Hutchinson, P. & Buki, A. Blood biomarkers for traumatic brain injury: A narrative review of current evidence. Brain Spine. 4, 102735 (2024).","journal-title":"Brain Spine"},{"key":"40271_CR26","doi-asserted-by":"publisher","first-page":"e2321554","DOI":"10.1001\/jamanetworkopen.2023.21554","volume":"6","author":"F Gonzalez-Ortiz","year":"2023","unstructured":"Gonzalez-Ortiz, F. et al. Association of serum brain-Derived Tau with clinical outcome and longitudinal change in patients with severe traumatic brain injury. JAMA Netw. Open. 6, e2321554 (2023).","journal-title":"JAMA Netw. Open."},{"key":"40271_CR27","unstructured":"Research, C. for D. E. and. Bioanalytical Method Validation Guidance for Industry. (2020). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/bioanalytical-method-validation-guidance-industry"},{"key":"40271_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fneur.2015.00179","volume":"6","author":"U Andreasson","year":"2015","unstructured":"Andreasson, U. et al. A practical guide to immunoassay method validation. Front. Neurol. 6, 179 (2015).","journal-title":"Front. Neurol."},{"key":"40271_CR29","doi-asserted-by":"publisher","DOI":"10.1101\/2024.12.26.24319657","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. Equivalence of plasma and serum for clinical measurement of p-tau217: comparative analyses of four blood-based assays. medRxiv https:\/\/doi.org\/10.1101\/2024.12.26.24319657 (2024).","journal-title":"medRxiv"},{"key":"40271_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s13024-024-00711-1","volume":"19","author":"X Zeng","year":"2024","unstructured":"Zeng, X. et al. Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting. Mol. Neurodegeneration. 19, 40 (2024).","journal-title":"Mol. Neurodegeneration"},{"key":"40271_CR31","unstructured":"BD-Tau Assay Kit -- Quanterix. Quanterix (2024). https:\/\/www.quanterix.com\/simoa-assay-kits\/bd-tau\/"},{"key":"40271_CR32","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1002\/alz.13516","volume":"20","author":"F Gonzalez-Ortiz","year":"2024","unstructured":"Gonzalez-Ortiz, F. et al. Levels of plasma brain-derived Tau and p-tau181 in Alzheimer\u2019s disease and rapidly progressive dementias. Alzheimer\u2019s Dement. 20, 745\u2013751 (2024).","journal-title":"Alzheimer\u2019s Dement."},{"key":"40271_CR33","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1177\/0271678X241293537","volume":"45","author":"JK Gundersen","year":"2025","unstructured":"Gundersen, J. K. et al. Neuronal plasma biomarkers in acute ischemic stroke. J. Cereb. Blood Flow. Metab. 45, 77\u201384 (2025).","journal-title":"J. Cereb. Blood Flow. Metab."},{"key":"40271_CR34","doi-asserted-by":"publisher","first-page":"fcae396","DOI":"10.1093\/braincomms\/fcae396","volume":"6","author":"F Leipp","year":"2024","unstructured":"Leipp, F. et al. Glial fibrillary acidic protein in alzheimer\u2019s disease: a narrative review. Brain Commun. 6, fcae396 (2024).","journal-title":"Brain Commun."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40271-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40271-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:35:42Z","timestamp":1774528542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40271-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,21]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40271-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,21]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Thomas K. Karikari: TKK has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, has served on advisory boards for Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. He has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well as meeting travel support from the Alzheimer\u2019s Association and Neurogen Biomarking LLC., outside the submitted work. TKK has received royalties from Bioventix for the transfer of specific antibodies and assays to third party organizations. He has received honoraria for speaker\/grant review engagements from the NIH, UPENN, UW\u2010Madison, the Cherry Blossom symposium, the HABS-HD\/ADNI4 Health Enhancement Scientific Program, Advent Health Translational Research Institute, Brain Health conference, Barcelona\u2010Pittsburgh conference, the International Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec Center for Drug Discovery, Canada, all outside of the submitted work. TKK is an inventor on several patents and provisional patents regarding biofluid biomarker methods, targets and reagents\/compositions, that may generate income for the institution and\/or self should they be licensed and\/or transferred to another organization. These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; US 63\/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer\u2019s Disease Patients; US 63\/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer\u2019s Disease; US 63\/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric tau and soluble tau aggregates.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patient samples were obtained with full written informed consent and approved by the University of Pittsburgh Institutional Review Board (ADRC study: MOD19110245-023; BTRC study: 19030228; PRARP study: 19110161). All research was performed in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"10124"}}